Cardiovascular DiseaseBIGPICNCT02501746
Bridging Income Generation With Group Integrated Care
A study testing Usual Clinical Care, Group Medical Visits and Microfinance Groups in people with Cardiovascular Disease and Diabetes, run by NYU Langone Health at 1 site in Kenya.
Trial summary
Specific Aims: Bridging Income Generation with GrouP Integrated Care (BIGPIC) Over 80% of cardiovascular disease (CVD) deaths occur in low- and middle-income countries (LMICs). Diabetes, a major risk factor for CVD, is also responsible for substantial morbidity and mortality in LMICs. Read more about this study
- Who is it for?
- Ages 35 years and older
- Conditions the study is for
- Cardiovascular Disease, Diabetes
- What is being tested?
- Usual Clinical Care, Group Medical Visits and Microfinance Groups
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 2,890 participants
- Where
- 1 siteKenya
- Study dates
- 6 Feb 2017to 29 Dec 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults in the CDM Program who:
- Have diabetes (fasting glucose ≥ 7 mmol/L);
- Are at increased risk for developing diabetes (impaired fasting glucose (fasting glucose 5.6 - 6.9 mmol/L);
- Have an elevated Leicester Risk Assessment score (≥ 7)
Who cannot join
- Acute illness requiring immediate medical attention;
- Terminal illness;
- Refusal to provide informed consent;
- Individuals who are pregnant or have HIV will be excluded, (automatically referred to a higher level of care within the AMPATH care system).
- Participation in the trial will not be contingent upon membership in a group. An intention-to-treat analysis will be conducted and the denominator in each cluster will include all eligible individuals who consent, irrespective of whether they are in a group, thus minimizing selection bias.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Bridging Income Generation With Group Integrated Care (BIGPIC)
Specific Aims: Bridging Income Generation with GrouP Integrated Care (BIGPIC) Over 80% of cardiovascular disease (CVD) deaths occur in low- and middle-income countries (LMICs). Diabetes, a major risk factor for CVD, is also responsible for substantial morbidity and mortality in LMICs. Elevated blood pressure (BP) increases CVD risk among individuals with diabetes and pre-diabetes; BP control is therefore a powerful way to reduce CVD risk. Cost-effective, culturally appropriate, and context-specific approaches are critical. Two promising strategies to improve health outcomes are group medical visits and microfinance. Both can increase quality of care, clinician-patient trust, self-efficacy, health savings, self-confidence, group cohesion, and social support. While these strategies have been successful in other contexts, their impact on CVD risk reduction among diabetics and pre-diabetics in low-resource settings is not known.
In partnership with the Government of Kenya, the Academic Model Providing Access to Healthcare (AMPATH) Partnership has expanded its clinical scope of work to include diabetes and hypertension. AMPATH has piloted group care and microfinance initiatives among patients with chronic diseases with promising early results. Both strategies are feasible, as is integration of group medical visits into microfinance groups. However, the effectiveness of these strategies individually, and in combination, on improving CVD risk is not known.
Read more
Thus, the objective of this proposal is to utilize a transdisciplinary implementation research approach to address the challenge of reducing CVD risk in low-resource settings. The central hypothesis is: group medical visits integrated into microfinance groups will be effective and cost-effective in reducing CVD risk among individuals with diabetes and at increased risk for diabetes in western Kenya, and that the key modifiable CVD risk factor to be addressed is BP. The research team hypothesize that group medical visits and microfinance may each reduce CVD risk, but the integration of group medical visits and microfinance will yield the largest gains. Also further hypothesize is that changes in social network characteristics may mediate the impact of interventions on the primary outcome, and that baseline social network characteristics may moderate the impact of interventions. To test these hypotheses and achieve the overall objectives, the following specific aims will be pursued:
Aim 1: Identify the contextual factors, facilitators, and barriers that may impact integration of group medical visits and microfinance for CVD risk reduction, using a combination of qualitative research methods: 1) baraza (traditional community gathering) form of inquiry; and 2) focus group discussions among individuals with diabetes or at increased risk for diabetes, microfinance group members, and rural health workers.
Subsidiary Aim 1.1: Use identified facilitators and barriers to develop a contextually and culturally appropriate integrated group medical visit-microfinance model to reduce CVD risk among individuals with diabetes or at increased risk of diabetes. This model's acceptability and feasibility will be assessed by conducting focus group discussions with patients, microfinance group members, and health workers.
Aim 2: Evaluate the effectiveness of group medical visits and microfinance groups for CVD risk reduction among individuals with diabetes or at increased risk for diabetes, by conducting a four-arm cluster randomized trial comparing: 1) usual clinical care; 2) usual clinical care plus microfinance groups only; 3) group medical visits only (no microfinance); and 4) group medical visits integrated into microfinance groups. The primary outcome measure will be one-year change in systolic blood pressure (SBP), and a key secondary outcome will be change in QRISK2 CVD risk score, which has been validated for Black Africans.
Subsidiary Aim 2.1: Conduct mediation analysis to evaluate the influence of changes in social network characteristics on intermediate factors and intervention outcomes and moderation analysis to evaluate the influence of baseline social network characteristics on effectiveness of interventions.
Aim 3: Evaluate the incremental cost-effectiveness of each intervention arm of the trial, in terms of costs per unit decrease in SBP, per percent change in CVD risk score, and per disability-adjusted life year saved.
This research project will add to the existing knowledge base on innovative, scalable, and sustainable strategies for reducing CVD risk in diabetes and other chronic diseases in LMICs and other low-resource settings. If proven to be effective, the investigators are poised to expand the approach beyond the trial, thus ensuring that this research will have a significant and positive health impact on a larger population.
Read the detailed description
The Academic Model Providing Access to Healthcare Partnership (AMPATH) was initiated in Kenya in 2001. In 2009, AMPATH was designated as a Center of Excellence for Cardiovascular and Pulmonary Disease Research by the NHLBI, and the program's research portfolio includes CVD, diabetes, and risk factors. Population-based prevalence of diabetes and hypertension in Kenya is not well known, and estimates vary according to technique, definitions, and geography. Prevalence rates range from 1% to 12% for diabetes, and 5% to 24% for hypertension. The lower ranges of these figures are self-reported disease and likely underestimate true prevalence due to low awareness of and screening for chronic diseases in this region.
In response to this substantial and growing burden of diabetes and hypertension, AMPATH has formed a Chronic Disease Management (CDM) Program , and established productive partnerships with the Kenyan government and local communities, in order to optimize care delivery for chronic diseases, such as diabetes and hypertension. AMPATH has a Memorandum of Understanding with the Kenyan Ministry of Public Health and Sanitation and the Ministry of Medical Services to test and evaluate innovative approaches to chronic disease management. The CDM Program developed a robust diabetes and hypertension management protocol derived from the International Diabetes Federation, World Health Organization (WHO), and Joint National Commission 7 and 8 guidelines for diabetes and hypertension management, using drugs contained in the Kenyan national formulary. The CDM program's interventions are delivered at Ministry of Health facilities with associated personnel. In addition, AMPATH has developed innovative, community-based solutions to ensure a consistent and secure supply of essential medicines. The CDM Program has enrolled over 2,000 patients with diabetes and 3,100 patients with hypertension, who are being cared for at nine rural health centers and 30 rural dispensaries. However, achieving BP control has been challenging; preliminary analysis of CDM Program data indicates that despite an average reduction in systolic BP (SBP) of 9.3 mmHg, only 30-40% of the CDM patient population have controlled BP. Thus, the program is actively seeking out innovative approaches to optimize care delivery and outcomes for patients.
AMPATH is also sensitive to the economic reality of its catchment population, recognizing that the average daily income for a substantial proportion of its clients is less than one US dollar per day. AMPATH has created a Safety Net Program to improve the economic security of clients without encouraging dependency, by promoting income-generating activities. The program has conducted preliminary work organizing microfinance groups, initially starting with HIV patients and pregnant women, and recently expanding to patients with diabetes and hypertension. Based on the model of Village-Level Savings and Loan Associations, AMPATH's microfinance program is a client-driven model that involves the creation of community savings groups. Thus, microfinance group members mobilize and manage their own savings, provide interest-bearing loans to group members, offer a limited form of financial insurance, and contribute to a social fund that is used in cases of emergency or welfare issues of group members. AMPATH also provides group members specific training on agribusiness, entrepreneurship, financial literacy, accounting, marketing, and group dynamics, to support engagement in sustainable income-generating activities. Since the program was launched in November 2010, there have been a total of 9,969 clients (83.8% female, 16.2% male), 508 groups, cumulative deposits of over $250,000 and social fund of nearly $23,000. The microfinance program has increased group membership by 14% with a retention rate of over 98%. An impact evaluation of the microfinance program revealed that group members have increased their monthly income by 10% and increased their weekly expenditure on food per household by 18%.
This research project will be conducted within the AMPATH catchment area, in six Divisions in western Kenya, each of which is geographically and administratively divided into Community Units (CUs) of approximately 6,000 individuals: Burnt Forest (4 CUs), Chulaimbo (8), Endebess (4), Kapsara (6), Matunda (4), and Moi's Bridge (6). Each Division has rural health facilities (rural health centers and rural dispensaries) staffed by clinical officers (mid-level practitioners) and nurses, while CHWs are in the villages. There has been a longstanding positive relationship among AMPATH, healthcare providers, and the communities. The CDM program has an established presence in all these communities.
Conceptual Framework Both microfinance and group medical visits can improve health outcomes through many mechanisms. The research team hypothesize that both interventions can cause changes in social network characteristics, leading to improved intermediate factors (diet, physical activity, medication adherence, and retention in care), ultimately yielding CVD risk reduction. It is also possible that both interventions can impact the intermediate factors and health outcomes independent of social network characteristics. Likewise, changes in social network characteristics may mediate the relationship between the interventions and CVD risk reduction independent of the intermediate factors. In addition, the interventions may be related to the health outcomes by other independent pathways. Finally, baseline differences in social network characteristics may moderate the impact of microfinance and group medical visits on CVD risk reduction.
Microfinance can increase savings (specifically health savings) and income, leading to increased ability to pay for healthier foods, medicines, diagnostic services, specialty consultation, and health insurance, thereby improving diet, medication adherence and retention in care. Microfinance can also lead to improved financial literacy, self-confidence, and decision-making agency, which can positively impact all of the intermediate factors, and subsequently CVD risk reduction. Likewise, group medical visits can increase the efficiency of care delivery, improve quality of care, encourage self-efficacy, and increase levels of clinician-patient trust, all of which can improve intermediate factors and thereby achieve CVD risk reduction. Both interventions can change social network characteristics within two to three months, and can create group cohesion, social support, and shared experiences, leading to a social environment more conducive to healthy behavior choices, medication adherence, and retention in care, maximizing their effectiveness. Social networks influence behavior through several theoretical mechanisms: information for behavior change, perceptions of social norms, how-to knowledge, and social comparisons. Through all of these mechanisms, individuals with diabetes or at increased risk of diabetes can achieve CVD risk reduction. It is likely that integrating group medical visits into microfinance groups may yield even better outcomes, through a combination of the mechanisms described above. To assess the independent effects of group medical visits, microfinance, and integrated group medical visits-microfinance groups, a four-arm trial is proposed. In addition, the investigators will assess whether changes in social network characteristics mediate the relationship between each intervention, the intermediate factors, and the primary outcome. Finally, the research team will assess if baseline differences in social network characteristics moderate the relationship between each intervention and the primary outcome. In sum, the Bridging Income Generation with GrouP Integrated Care (BIGPIC) study will be able to assess comprehensively the relationship between microfinance, group medical visits, social networks, intermediate factors, and CVD risk reduction among individuals with diabetes and at increased risk of diabetes.
Subsidiary Aim 1.1: Develop a contextually and culturally appropriate integrated group medical visit-microfinance model for CVD risk reduction AMPATH's Community Strategy Initiative routinely engages with existing community-based governance structures to gather input and feedback on any community-based initiative. In addition, the AMPATH Safety Net Program routinely gathers feedback from community members, and the microfinance intervention has evolved as a result of that input. The research team will adhere to these same principles in this proposed project. A participatory, iterative design process will be pursed and create a "design team" consisting of one facilitator, two research team members, two clinicians, two CHWs, two patients, and the research assistant. The design team will meet for several design sessions over a period of four weeks. The design process will involve three phases: brainstorming, conceptualization, and creation. During brainstorming, the facilitator will first acquaint the team with the findings of the qualitative study and specify the criteria for the integrated group medical visit-microfinance intervention (i.e. prototype as described in Aim 2 below, while incorporating content from the focus groups and mabaraza). In the conceptualization phase, the team will evaluate advantages and disadvantages of ideas resulting from brainstorming, and will develop a more concrete model. The creation phase will involve the actual creation of the integrated group medical visit-microfinance model for CVD risk reduction among individuals with diabetes and at increased risk for diabetes. Educational materials will be developed in English, Kiswahili, and other local languages using standard approaches to translation and back-translation. Once the integrated group medical visit-microfinance model is developed, two FGDs will be conducted each with patients, microfinance group members, and health workers, in order to assess acceptability and feasibility. The investigators have previously used this type of approach with positive community feedback.
Aim 2: Evaluate the effectiveness of group medical visits and microfinance for CVD risk reduction. The effectiveness of group medical visits and microfinance groups for CVD risk reduction will be evaluated among individuals with diabetes or at increased risk for diabetes, by conducting a four-arm cluster randomized trial . The primary outcome measure will be one-year change in SBP, and a key secondary outcome measure will be change in CVD risk score. Randomization will occur at the level of the CU (cluster), and will be stratified by Division. Each of the 32 CUs will be randomly allocated (eight CUs per arm).
Preliminary Data As above, AMPATH's CDM Program has an extensive network of rural health facilities delivering care for diabetes and hypertension. Although there have been notable improvements in clinical measures, nearly 60% do not link to care and nearly 50% do not remain in care once enrolled. Women are twice as likely to engage in care as men. The CDM Program has piloted various forms of group care for diabetes and CVD risk factors and has determined that group care is feasible and acceptable in this setting. The program implemented diabetes self-management support groups providing community-based peer support as a supplement to health facility-based clinical care, education, and counseling. These groups included a peer leader with specific training, and they had regularly scheduled meetings during which members learned about behavioral modification, self-management strategies, and problem-solving approaches. Analysis of 148 subjects at three months revealed that 76% of members attended group meetings at least once per month. Median hemoglobin A1C improved from 9.6% to 9.1%, but there were no significant changes in BP, body-mass index, or waist circumference.
The CDM Program and Safety Net Program have also collaborated to integrate microfinance groups and group medical visits, and have demonstrated the feasibility of this integrated approach. One-year results of this preliminary work (BIGPIC Pilot) are now available and appear promising. Six integrated groups were newly formed comprising 160 members, of whom 90 (over 50%) were patients with diabetes and hypertension. More women attended the initial screening (72%), and were therefore over-represented. After invitation to create integrated group medical visit- microfinance groups, women were slightly more likely to participate than men (83% vs. 74%).
Linkage, retention, and change in SBP comparing usual care vs. BIGPIC Pilot. Model of Care Linkage to care Retention in care
∆ SBP after 1 year Usual Care 42% 50%
- 9.3 mmHg BIGPIC Pilot 66% 66%
- 21.0 mmHg At one year, members had accumulated deposits totaling $7,500, with a social fund of $1150. The loan repayment rate was 97.8%. Progress out of Poverty Index mean score increased from 36 to 44, in addition to other economic indicators. Table 1 provides a summary of linkage, retention, and SBP change, comparing usual care and the BIGPIC Pilot. In year 2, membership has increased by 86.9%, indicative of a very favorable response by the community.
Participants Within each CU, AMPATH has initiated home-based testing and community-level screening of glucose and BP, with a plan to cover one-third of each CU's population every year. Adult individuals with elevated BP (SBP ≥ 140 or diastolic BP (DBP) ≥ 90) or elevated random blood glucose (≥ 8.1 mmol/L) will be assigned a unique AMPATH Medical Record System identification number and referred to the local rural health facility for further evaluation and confirmation of disease status. At the health facility, each individual will have a repeat BP and fasting glucose measured, and those who meet the designated cutoffs (repeat SBP ≥ 140 or DBP ≥ 90; fasting glucose ≥ 7 mmol/L) will be entered into the CDM Program.
- Conditions
- Cardiovascular Disease, Diabetes
- Being tested
- Usual Clinical Care, Group Medical Visits, Microfinance Groups
- Keywords
- Group medical care, Microfinance, Hypertension, Community-based intervention, Global health
- Medical subject headings
- Cardiovascular Diseases, Diabetes Mellitus, Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Usual Clinical CareOther
Also called UC
Non-hypertensive diabetic individuals will not be pharmacologically treated for BP reduction; those with BP 120-139/80-89 will be advised on lifestyle changes to reduce BP as recommended by the 2013 Standards of Medical Care in Diabetes. Care will be provided to each individual at the rural health facility by a rural clinician mentored by the CDM Program, including regular monthly consultation, vital signs, physical examination, and prescriptions. CHWs will assist with linkage and retention of patients to the care program, and provide health education. The 12-month follow-up BP will be measured in the rural health facility, in order to mimic real-world practice. If the patient does not present to the rural health facility for the 12-month visit, the local CHW will trace the patient at home and will check the 12-month BP at that time, again consistent with real-world conditions.
Group Medical VisitsOther
Also called GMV
The CHW will facilitate a group discussion about a self-care or health education topic chosen by the group while the rural clinician reviews the BP, sugar, and adherence data to determine a clinical recommendation as per the CDM clinical algorithm. which is communicated to each individual patient privately by the rural clinician in a five-minute "breakout time". The rural clinician will not change the regimen for non adherence but instead will use the breakout time to assess barriers to adherence and try to help the patient identify solutions to those barriers.The breakout time can also be used to perform a physical examination or other assessments as clinically required. After all patients have had individual consultations with the rural clinician, the entire group re-convenes for a closing session, which consists of a question-and-answer period and determination of the next session's self-care or health education topic.
Microfinance GroupsOther
Also called MF
The rural clinician and the CHW will organize a meeting with AMPATH's Safety Net Program representatives, who will introduce the concept of microfinance groups, the potential benefits, and encourage the formation of new groups to meet monthly. The microfinance groups need to incorporate an element of self-selection and self-formation, so that individuals have the freedom to choose with whom they will create a group. The groups are therefore formed voluntarily, and usually along geographical boundaries, which facilitates participation, retention, and meeting logistics.
| Study group | Role | What they receive |
|---|---|---|
| Usual Clinical Care (UC) | Active comparator | This will be the current standard of care delivered by the AMPATH CDM Program, in accordance with the management protocol for diabetes and hypertension. Receives: Other: Usual Clinical Care |
| Usual clinical care plus microfinance groups only (MF) | Experimental | Usual clinical care as described above. In addition, participants will be encouraged to create microfinance groups organized and supported by AMPATH's Safety Net Program. Receives: Other: Usual Clinical Care; Other: Microfinance Groups |
| Group medical visits only (GMV) | Experimental | Participants randomized to this arm will be invited to create a group that will attend monthly group medical visits at the rural health facility. Each group medical visit will be staffed by both the rural clinician and the local CHW (educator). Groups will consist of the same patients at each of 12 monthly visits. Each visit will begin with the measurement of fasting blood glucose and resting electronic BP, as well as the ascertainment of medication regimens for BP and diabetes, and extent of adherence to the prescribed regimen. Receives: Other: Group Medical Visits |
| GMV integrated into GMV-MF | Experimental | Clinical care will be provided in the form of group medical visits, and the participants will be actively recruited to create microfinance groups. Thus, the monthly group medical visit will be integrated into the microfinance groups, wherein the visit will consist of an initial microfinance portion, followed by the group medical visit. Receives: Other: Group Medical Visits |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Systolic Blood Pressure
Change in Systolic Blood Pressure at 12 months as compared to baseline
Measured: Baseline and 12 months
Secondary outcomes (1)
Change in cardiovascular disease (CVD) risk Score
Change in overall CVD risk as measured by the QRISK2 score, which has been validated for calculating 10-year CVD event risk for Black Africans.
Measured: Baseline and 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jul 2015 (estimated)
- Study start6 Feb 2017
- Primary completion29 Dec 2019
- Study completion29 Dec 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Cardiovascular DiseaseStudies of the same condition, open and under way.
- More trials run by NYU Langone HealthThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 2,890 participants (actual)
Sponsor and investigators
- Lead sponsor
- NYU Langone Health
- Sponsor type
- University, hospital or other
- Collaborators
- Moi University College of Health Sciences, Brown University, Duke University, Purdue University, National Heart, Lung, and Blood Institute (NHLBI), Icahn School of Medicine at Mount Sinai
- Responsible party
- Sponsor
- Investigators
- Rajesh Vedanthan, MD, MPH, Principal investigator, NYU Langone Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02501746
- Sponsor's protocol ID
- 18-01260
- Other IDs
- 1R01HL125487
- Acronym
- BIGPIC
- Status last verified
- Jun 2020
- First submitted
- 15 Jul 2015
- Last updated
- 17 Jun 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Chay J, Su RJ, Kamano JH, Andama B, Bloomfield GS, Delong AK, Horowitz CR, Menya D, Mugo R, Orango V, Pastakia SD, Wanyonyi C, Vedanthan R, Finkelstein EA. Cost-effectiveness of group medical visits and microfinance interventions versus usual care to manage hypertension in Kenya: a secondary modelling analysis of data from the Bridging Income Generation with Group Integrated Care (BIGPIC) trial. Lancet Glob Health. 2024 Aug;12(8):e1331-e1342. doi: 10.1016/S2214-109X(24)00188-8.
PubMed 39030063Gala P, Kamano JH, Vazquez Sanchez M, Mugo R, Orango V, Pastakia S, Horowitz C, Hogan JW, Vedanthan R. Cross-sectional analysis of factors associated with medication adherence in western Kenya. BMJ Open. 2023 Sep 5;13(9):e072358. doi: 10.1136/bmjopen-2023-072358.
PubMed 37669842Pillsbury MKM, Mwangi E, Andesia J, Njuguna B, Bloomfield GS, Chepchumba A, Kamano J, Mercer T, Miheso J, Pastakia SD, Pathak S, Thakkar A, Naanyu V, Akwanalo C, Vedanthan R. Human-centered implementation research: a new approach to develop and evaluate implementation strategies for strengthening referral networks for hypertension in western Kenya. BMC Health Serv Res. 2021 Sep 3;21(1):910. doi: 10.1186/s12913-021-06930-2.
PubMed 34479556Ruchman SG, Delong AK, Kamano JH, Bloomfield GS, Chrysanthopoulou SA, Fuster V, Horowitz CR, Kiptoo P, Matelong W, Mugo R, Naanyu V, Orango V, Pastakia SD, Valente TW, Hogan JW, Vedanthan R. Egocentric social network characteristics and cardiovascular risk among patients with hypertension or diabetes in western Kenya: a cross-sectional analysis from the BIGPIC trial. BMJ Open. 2021 Sep 2;11(9):e049610. doi: 10.1136/bmjopen-2021-049610.
PubMed 34475172Vedanthan R, Kamano JH, Chrysanthopoulou SA, Mugo R, Andama B, Bloomfield GS, Chesoli CW, DeLong AK, Edelman D, Finkelstein EA, Horowitz CR, Manyara S, Menya D, Naanyu V, Orango V, Pastakia SD, Valente TW, Hogan JW, Fuster V. Group Medical Visit and Microfinance Intervention for Patients With Diabetes or Hypertension in Kenya. J Am Coll Cardiol. 2021 Apr 27;77(16):2007-2018. doi: 10.1016/j.jacc.2021.03.002.
PubMed 33888251Leung CL, Naert M, Andama B, Dong R, Edelman D, Horowitz C, Kiptoo P, Manyara S, Matelong W, Matini E, Naanyu V, Nyariki S, Pastakia S, Valente T, Fuster V, Bloomfield GS, Kamano J, Vedanthan R. Human-centered design as a guide to intervention planning for non-communicable diseases: the BIGPIC study from Western Kenya. BMC Health Serv Res. 2020 May 12;20(1):415. doi: 10.1186/s12913-020-05199-1.
PubMed 32398131
Study at a glance
From the registry record, last updated by the sponsor on 17 Jun 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Bridging Income Generation With Group Integrated Care (BIGPIC)
- ClinicalTrials.gov ID
- NCT02501746
- Acronym / sponsor ID
- BIGPIC / 18-01260
- Conditions
- Cardiovascular Disease, Diabetes
- Keywords
- Group medical care, Microfinance, Hypertension, Community-based intervention, Global health
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 2,890 participants (actual)
- Lead sponsor
- NYU Langone HealthUniversity, hospital or other
- Collaborators
- Moi University College of Health Sciences, Brown University, Duke University, Purdue University, National Heart, Lung, and Blood Institute (NHLBI), Icahn School of Medicine at Mount Sinai
- Study start
- 6 Feb 2017 (actual)
- Primary completion
- 29 Dec 2019 (actual)
- Study completion
- 29 Dec 2019 (actual)
- First posted
- 17 Jul 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Specific Aims: Bridging Income Generation with GrouP Integrated Care (BIGPIC) Over 80% of cardiovascular disease (CVD) deaths occur in low- and middle-income countries (LMICs). Diabetes, a major risk factor for CVD, is also responsible for substantial morbidity and mortality in LMICs. Elevated blood pressure (BP) increases CVD risk among individuals with diabetes and pre-diabetes; BP control is therefore a powerful way to reduce CVD risk. Cost-effective, culturally appropriate, and context-specific approaches are critical. Two promising strategies to improve health outcomes are group medical visits and microfinance. Both can increase quality of care, clinician-patient trust, self-efficacy, health savings, self-confidence, group cohesion, and social support. While these strategies have been successful in other contexts, their impact on CVD risk reduction among diabetics and pre-diabetics in low-resource settings is not known.
In partnership with the Government of Kenya, the Academic Model Providing Access to Healthcare (AMPATH) Partnership has expanded its clinical scope of work to include diabetes and hypertension. AMPATH has piloted group care and microfinance initiatives among patients with chronic diseases with promising early results. Both strategies are feasible, as is integration of group medical visits into microfinance groups. However, the effectiveness of these strategies individually, and in combination, on improving CVD risk is not known.
Thus, the objective of this proposal is to utilize a transdisciplinary implementation research approach to address the challenge of reducing CVD risk in low-resource settings. The central hypothesis is: group medical visits integrated into microfinance groups will be effective and cost-effective in reducing CVD risk among individuals with diabetes and at increased risk for diabetes in western Kenya, and that the key modifiable CVD risk factor to be addressed is BP. The research team hypothesize that group medical visits and microfinance may each reduce CVD risk, but the integration of group medical visits and microfinance will yield the largest gains. Also further hypothesize is that changes in social network characteristics may mediate the impact of interventions on the primary outcome, and that baseline social network characteristics may moderate the impact of interventions. To test these hypotheses and achieve the overall objectives, the following specific aims will be pursued:
Aim 1: Identify the contextual factors, facilitators, and barriers that may impact integration of group medical visits and microfinance for CVD risk reduction, using a combination of qualitative research methods: 1) baraza (traditional community gathering) form of inquiry; and 2) focus group discussions among individuals with diabetes or at increased risk for diabetes, microfinance group members, and rural health workers.
Subsidiary Aim 1.1: Use identified facilitators and barriers to develop a contextually and culturally appropriate integrated group medical visit-microfinance model to reduce CVD risk among individuals with diabetes or at increased risk of diabetes. This model's acceptability and feasibility will be assessed by conducting focus group discussions with patients, microfinance group members, and health workers.
Aim 2: Evaluate the effectiveness of group medical visits and microfinance groups for CVD risk reduction among individuals with diabetes or at increased risk for diabetes, by conducting a four-arm cluster randomized trial comparing: 1) usual clinical care; 2) usual clinical care plus microfinance groups only; 3) group medical visits only (no microfinance); and 4) group medical visits integrated into microfinance groups. The primary outcome measure will be one-year change in systolic blood pressure (SBP), and a key secondary outcome will be change in QRISK2 CVD risk score, which has been validated for Black Africans.
Subsidiary Aim 2.1: Conduct mediation analysis to evaluate the influence of changes in social network characteristics on intermediate factors and intervention outcomes and moderation analysis to evaluate the influence of baseline social network characteristics on effectiveness of interventions.
Aim 3: Evaluate the incremental cost-effectiveness of each intervention arm of the trial, in terms of costs per unit decrease in SBP, per percent change in CVD risk score, and per disability-adjusted life year saved.
This research project will add to the existing knowledge base on innovative, scalable, and sustainable strategies for reducing CVD risk in diabetes and other chronic diseases in LMICs and other low-resource settings. If proven to be effective, the investigators are poised to expand the approach beyond the trial, thus ensuring that this research will have a significant and positive health impact on a larger population.
Detailed description
The Academic Model Providing Access to Healthcare Partnership (AMPATH) was initiated in Kenya in 2001. In 2009, AMPATH was designated as a Center of Excellence for Cardiovascular and Pulmonary Disease Research by the NHLBI, and the program's research portfolio includes CVD, diabetes, and risk factors. Population-based prevalence of diabetes and hypertension in Kenya is not well known, and estimates vary according to technique, definitions, and geography. Prevalence rates range from 1% to 12% for diabetes, and 5% to 24% for hypertension. The lower ranges of these figures are self-reported disease and likely underestimate true prevalence due to low awareness of and screening for chronic diseases in this region.
In response to this substantial and growing burden of diabetes and hypertension, AMPATH has formed a Chronic Disease Management (CDM) Program , and established productive partnerships with the Kenyan government and local communities, in order to optimize care delivery for chronic diseases, such as diabetes and hypertension. AMPATH has a Memorandum of Understanding with the Kenyan Ministry of Public Health and Sanitation and the Ministry of Medical Services to test and evaluate innovative approaches to chronic disease management. The CDM Program developed a robust diabetes and hypertension management protocol derived from the International Diabetes Federation, World Health Organization (WHO), and Joint National Commission 7 and 8 guidelines for diabetes and hypertension management, using drugs contained in the Kenyan national formulary. The CDM program's interventions are delivered at Ministry of Health facilities with associated personnel. In addition, AMPATH has developed innovative, community-based solutions to ensure a consistent and secure supply of essential medicines. The CDM Program has enrolled over 2,000 patients with diabetes and 3,100 patients with hypertension, who are being cared for at nine rural health centers and 30 rural dispensaries. However, achieving BP control has been challenging; preliminary analysis of CDM Program data indicates that despite an average reduction in systolic BP (SBP) of 9.3 mmHg, only 30-40% of the CDM patient population have controlled BP. Thus, the program is actively seeking out innovative approaches to optimize care delivery and outcomes for patients.
AMPATH is also sensitive to the economic reality of its catchment population, recognizing that the average daily income for a substantial proportion of its clients is less than one US dollar per day. AMPATH has created a Safety Net Program to improve the economic security of clients without encouraging dependency, by promoting income-generating activities. The program has conducted preliminary work organizing microfinance groups, initially starting with HIV patients and pregnant women, and recently expanding to patients with diabetes and hypertension. Based on the model of Village-Level Savings and Loan Associations, AMPATH's microfinance program is a client-driven model that involves the creation of community savings groups. Thus, microfinance group members mobilize and manage their own savings, provide interest-bearing loans to group members, offer a limited form of financial insurance, and contribute to a social fund that is used in cases of emergency or welfare issues of group members. AMPATH also provides group members specific training on agribusiness, entrepreneurship, financial literacy, accounting, marketing, and group dynamics, to support engagement in sustainable income-generating activities. Since the program was launched in November 2010, there have been a total of 9,969 clients (83.8% female, 16.2% male), 508 groups, cumulative deposits of over $250,000 and social fund of nearly $23,000. The microfinance program has increased group membership by 14% with a retention rate of over 98%. An impact evaluation of the microfinance program revealed that group members have increased their monthly income by 10% and increased their weekly expenditure on food per household by 18%.
This research project will be conducted within the AMPATH catchment area, in six Divisions in western Kenya, each of which is geographically and administratively divided into Community Units (CUs) of approximately 6,000 individuals: Burnt Forest (4 CUs), Chulaimbo (8), Endebess (4), Kapsara (6), Matunda (4), and Moi's Bridge (6). Each Division has rural health facilities (rural health centers and rural dispensaries) staffed by clinical officers (mid-level practitioners) and nurses, while CHWs are in the villages. There has been a longstanding positive relationship among AMPATH, healthcare providers, and the communities. The CDM program has an established presence in all these communities.
Conceptual Framework Both microfinance and group medical visits can improve health outcomes through many mechanisms. The research team hypothesize that both interventions can cause changes in social network characteristics, leading to improved intermediate factors (diet, physical activity, medication adherence, and retention in care), ultimately yielding CVD risk reduction. It is also possible that both interventions can impact the intermediate factors and health outcomes independent of social network characteristics. Likewise, changes in social network characteristics may mediate the relationship between the interventions and CVD risk reduction independent of the intermediate factors. In addition, the interventions may be related to the health outcomes by other independent pathways. Finally, baseline differences in social network characteristics may moderate the impact of microfinance and group medical visits on CVD risk reduction.
Microfinance can increase savings (specifically health savings) and income, leading to increased ability to pay for healthier foods, medicines, diagnostic services, specialty consultation, and health insurance, thereby improving diet, medication adherence and retention in care. Microfinance can also lead to improved financial literacy, self-confidence, and decision-making agency, which can positively impact all of the intermediate factors, and subsequently CVD risk reduction. Likewise, group medical visits can increase the efficiency of care delivery, improve quality of care, encourage self-efficacy, and increase levels of clinician-patient trust, all of which can improve intermediate factors and thereby achieve CVD risk reduction. Both interventions can change social network characteristics within two to three months, and can create group cohesion, social support, and shared experiences, leading to a social environment more conducive to healthy behavior choices, medication adherence, and retention in care, maximizing their effectiveness. Social networks influence behavior through several theoretical mechanisms: information for behavior change, perceptions of social norms, how-to knowledge, and social comparisons. Through all of these mechanisms, individuals with diabetes or at increased risk of diabetes can achieve CVD risk reduction. It is likely that integrating group medical visits into microfinance groups may yield even better outcomes, through a combination of the mechanisms described above. To assess the independent effects of group medical visits, microfinance, and integrated group medical visits-microfinance groups, a four-arm trial is proposed. In addition, the investigators will assess whether changes in social network characteristics mediate the relationship between each intervention, the intermediate factors, and the primary outcome. Finally, the research team will assess if baseline differences in social network characteristics moderate the relationship between each intervention and the primary outcome. In sum, the Bridging Income Generation with GrouP Integrated Care (BIGPIC) study will be able to assess comprehensively the relationship between microfinance, group medical visits, social networks, intermediate factors, and CVD risk reduction among individuals with diabetes and at increased risk of diabetes.
Subsidiary Aim 1.1: Develop a contextually and culturally appropriate integrated group medical visit-microfinance model for CVD risk reduction AMPATH's Community Strategy Initiative routinely engages with existing community-based governance structures to gather input and feedback on any community-based initiative. In addition, the AMPATH Safety Net Program routinely gathers feedback from community members, and the microfinance intervention has evolved as a result of that input. The research team will adhere to these same principles in this proposed project. A participatory, iterative design process will be pursed and create a "design team" consisting of one facilitator, two research team members, two clinicians, two CHWs, two patients, and the research assistant. The design team will meet for several design sessions over a period of four weeks. The design process will involve three phases: brainstorming, conceptualization, and creation. During brainstorming, the facilitator will first acquaint the team with the findings of the qualitative study and specify the criteria for the integrated group medical visit-microfinance intervention (i.e. prototype as described in Aim 2 below, while incorporating content from the focus groups and mabaraza). In the conceptualization phase, the team will evaluate advantages and disadvantages of ideas resulting from brainstorming, and will develop a more concrete model. The creation phase will involve the actual creation of the integrated group medical visit-microfinance model for CVD risk reduction among individuals with diabetes and at increased risk for diabetes. Educational materials will be developed in English, Kiswahili, and other local languages using standard approaches to translation and back-translation. Once the integrated group medical visit-microfinance model is developed, two FGDs will be conducted each with patients, microfinance group members, and health workers, in order to assess acceptability and feasibility. The investigators have previously used this type of approach with positive community feedback.
Aim 2: Evaluate the effectiveness of group medical visits and microfinance for CVD risk reduction. The effectiveness of group medical visits and microfinance groups for CVD risk reduction will be evaluated among individuals with diabetes or at increased risk for diabetes, by conducting a four-arm cluster randomized trial . The primary outcome measure will be one-year change in SBP, and a key secondary outcome measure will be change in CVD risk score. Randomization will occur at the level of the CU (cluster), and will be stratified by Division. Each of the 32 CUs will be randomly allocated (eight CUs per arm).
Preliminary Data As above, AMPATH's CDM Program has an extensive network of rural health facilities delivering care for diabetes and hypertension. Although there have been notable improvements in clinical measures, nearly 60% do not link to care and nearly 50% do not remain in care once enrolled. Women are twice as likely to engage in care as men. The CDM Program has piloted various forms of group care for diabetes and CVD risk factors and has determined that group care is feasible and acceptable in this setting. The program implemented diabetes self-management support groups providing community-based peer support as a supplement to health facility-based clinical care, education, and counseling. These groups included a peer leader with specific training, and they had regularly scheduled meetings during which members learned about behavioral modification, self-management strategies, and problem-solving approaches. Analysis of 148 subjects at three months revealed that 76% of members attended group meetings at least once per month. Median hemoglobin A1C improved from 9.6% to 9.1%, but there were no significant changes in BP, body-mass index, or waist circumference.
The CDM Program and Safety Net Program have also collaborated to integrate microfinance groups and group medical visits, and have demonstrated the feasibility of this integrated approach. One-year results of this preliminary work (BIGPIC Pilot) are now available and appear promising. Six integrated groups were newly formed comprising 160 members, of whom 90 (over 50%) were patients with diabetes and hypertension. More women attended the initial screening (72%), and were therefore over-represented. After invitation to create integrated group medical visit- microfinance groups, women were slightly more likely to participate than men (83% vs. 74%).
Linkage, retention, and change in SBP comparing usual care vs. BIGPIC Pilot. Model of Care Linkage to care Retention in care
∆ SBP after 1 year Usual Care 42% 50%
- 9.3 mmHg BIGPIC Pilot 66% 66%
- 21.0 mmHg At one year, members had accumulated deposits totaling $7,500, with a social fund of $1150. The loan repayment rate was 97.8%. Progress out of Poverty Index mean score increased from 36 to 44, in addition to other economic indicators. Table 1 provides a summary of linkage, retention, and SBP change, comparing usual care and the BIGPIC Pilot. In year 2, membership has increased by 86.9%, indicative of a very favorable response by the community.
Participants Within each CU, AMPATH has initiated home-based testing and community-level screening of glucose and BP, with a plan to cover one-third of each CU's population every year. Adult individuals with elevated BP (SBP ≥ 140 or diastolic BP (DBP) ≥ 90) or elevated random blood glucose (≥ 8.1 mmol/L) will be assigned a unique AMPATH Medical Record System identification number and referred to the local rural health facility for further evaluation and confirmation of disease status. At the health facility, each individual will have a repeat BP and fasting glucose measured, and those who meet the designated cutoffs (repeat SBP ≥ 140 or DBP ≥ 90; fasting glucose ≥ 7 mmol/L) will be entered into the CDM Program.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Usual Clinical Care (UC) | Active comparator | Other: Usual Clinical CareThis will be the current standard of care delivered by the AMPATH CDM Program, in accordance with the management protocol for diabetes and hypertension. |
| Usual clinical care plus microfinance groups only (MF) | Experimental | Other: Usual Clinical Care, Other: Microfinance GroupsUsual clinical care as described above. In addition, participants will be encouraged to create microfinance groups organized and supported by AMPATH's Safety Net Program. |
| Group medical visits only (GMV) | Experimental | Other: Group Medical VisitsParticipants randomized to this arm will be invited to create a group that will attend monthly group medical visits at the rural health facility. Each group medical visit will be staffed by both the rural clinician and the local CHW (educator). Groups will consist of the same patients at each of 12 monthly visits. Each visit will begin with the measurement of fasting blood glucose and resting electronic BP, as well as the ascertainment of medication regimens for BP and diabetes, and extent of adherence to the prescribed regimen. |
| GMV integrated into GMV-MF | Experimental | Other: Group Medical VisitsClinical care will be provided in the form of group medical visits, and the participants will be actively recruited to create microfinance groups. Thus, the monthly group medical visit will be integrated into the microfinance groups, wherein the visit will consist of an initial microfinance portion, followed by the group medical visit. |
Who may qualify
- Ages
- 35 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Have diabetes (fasting glucose ≥ 7 mmol/L);
- Are at increased risk for developing diabetes (impaired fasting glucose (fasting glucose 5.6 - 6.9 mmol/L);
- Have an elevated Leicester Risk Assessment score (≥ 7)
Key exclusion criteria (5 listed)
- Acute illness requiring immediate medical attention;
- Terminal illness;
- Refusal to provide informed consent;
- Individuals who are pregnant or have HIV will be excluded, (automatically referred to a higher level of care within the AMPATH care system).
- Participation in the trial will not be contingent upon membership in a group. An intention-to-treat analysis will be conducted and the denominator in each cluster will include all eligible individuals who consent, irrespective of whether they are in a group, thus minimizing selection bias.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Usual Clinical CareAlso: UCNon-hypertensive diabetic individuals will not be pharmacologically treated for BP reduction; those with BP 120-139/80-89 will be advised on lifestyle changes to reduce BP as recommended by the 2013 Standards of Medical Care in Diabetes. Care will be provided to each individual at the rural health facility by a rural clinician mentored by the CDM Program, including regular monthly consultation, vital signs, physical examination, and prescriptions. CHWs will assist with linkage and retention of patients to the care program, and provide health education. The 12-month follow-up BP will be measured in the rural health facility, in order to mimic real-world practice. If the patient does not present to the rural health facility for the 12-month visit, the local CHW will trace the patient at home and will check the 12-month BP at that time, again consistent with real-world conditions. | Other | Usual Clinical Care (UC), Usual clinical care plus microfinance groups only (MF) |
| Group Medical VisitsAlso: GMVThe CHW will facilitate a group discussion about a self-care or health education topic chosen by the group while the rural clinician reviews the BP, sugar, and adherence data to determine a clinical recommendation as per the CDM clinical algorithm. which is communicated to each individual patient privately by the rural clinician in a five-minute "breakout time". The rural clinician will not change the regimen for non adherence but instead will use the breakout time to assess barriers to adherence and try to help the patient identify solutions to those barriers.The breakout time can also be used to perform a physical examination or other assessments as clinically required. After all patients have had individual consultations with the rural clinician, the entire group re-convenes for a closing session, which consists of a question-and-answer period and determination of the next session's self-care or health education topic. | Other | GMV integrated into GMV-MF, Group medical visits only (GMV) |
| Microfinance GroupsAlso: MFThe rural clinician and the CHW will organize a meeting with AMPATH's Safety Net Program representatives, who will introduce the concept of microfinance groups, the potential benefits, and encourage the formation of new groups to meet monthly. The microfinance groups need to incorporate an element of self-selection and self-formation, so that individuals have the freedom to choose with whom they will create a group. The groups are therefore formed voluntarily, and usually along geographical boundaries, which facilitates participation, retention, and meeting logistics. | Other | Usual clinical care plus microfinance groups only (MF) |
Primary outcome
Change in Systolic Blood Pressure
Time frame: Baseline and 12 months
Change in Systolic Blood Pressure at 12 months as compared to baseline
1 secondary outcome
Change in cardiovascular disease (CVD) risk Score
Time frame: Baseline and 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jun 2020.
- Derived from this study: PubMed 39030063Chay J, Su RJ, Kamano JH, Andama B, Bloomfield GS, Delong AK, Horowitz CR, Menya D, Mugo R, Orango V, Pastakia SD, Wanyonyi C, Vedanthan R, Finkelstein EA. Cost-effectiveness of group medical visits and microfinance interventions versus usual care to manage hypertension in Kenya: a secondary modelling analysis of data from the Bridging Income Generation with Group Integrated Care (BIGPIC) trial. Lancet Glob Health. 2024 Aug;12(8):e1331-e1342. doi: 10.1016/S2214-109X(24)00188-8.
- Derived from this study: PubMed 37669842Gala P, Kamano JH, Vazquez Sanchez M, Mugo R, Orango V, Pastakia S, Horowitz C, Hogan JW, Vedanthan R. Cross-sectional analysis of factors associated with medication adherence in western Kenya. BMJ Open. 2023 Sep 5;13(9):e072358. doi: 10.1136/bmjopen-2023-072358.
- Derived from this study: PubMed 34479556Pillsbury MKM, Mwangi E, Andesia J, Njuguna B, Bloomfield GS, Chepchumba A, Kamano J, Mercer T, Miheso J, Pastakia SD, Pathak S, Thakkar A, Naanyu V, Akwanalo C, Vedanthan R. Human-centered implementation research: a new approach to develop and evaluate implementation strategies for strengthening referral networks for hypertension in western Kenya. BMC Health Serv Res. 2021 Sep 3;21(1):910. doi: 10.1186/s12913-021-06930-2.
- Derived from this study: PubMed 34475172Ruchman SG, Delong AK, Kamano JH, Bloomfield GS, Chrysanthopoulou SA, Fuster V, Horowitz CR, Kiptoo P, Matelong W, Mugo R, Naanyu V, Orango V, Pastakia SD, Valente TW, Hogan JW, Vedanthan R. Egocentric social network characteristics and cardiovascular risk among patients with hypertension or diabetes in western Kenya: a cross-sectional analysis from the BIGPIC trial. BMJ Open. 2021 Sep 2;11(9):e049610. doi: 10.1136/bmjopen-2021-049610.
- Derived from this study: PubMed 33888251Vedanthan R, Kamano JH, Chrysanthopoulou SA, Mugo R, Andama B, Bloomfield GS, Chesoli CW, DeLong AK, Edelman D, Finkelstein EA, Horowitz CR, Manyara S, Menya D, Naanyu V, Orango V, Pastakia SD, Valente TW, Hogan JW, Fuster V. Group Medical Visit and Microfinance Intervention for Patients With Diabetes or Hypertension in Kenya. J Am Coll Cardiol. 2021 Apr 27;77(16):2007-2018. doi: 10.1016/j.jacc.2021.03.002.
- Derived from this study: PubMed 32398131Leung CL, Naert M, Andama B, Dong R, Edelman D, Horowitz C, Kiptoo P, Manyara S, Matelong W, Matini E, Naanyu V, Nyariki S, Pastakia S, Valente T, Fuster V, Bloomfield GS, Kamano J, Vedanthan R. Human-centered design as a guide to intervention planning for non-communicable diseases: the BIGPIC study from Western Kenya. BMC Health Serv Res. 2020 May 12;20(1):415. doi: 10.1186/s12913-020-05199-1.
Related trials for Cardiovascular Disease
Recruiting
ELEVATE-HFpEF Clinical Study
Heart Failure With Preserved Ejection Fraction (HFpEF)
Not yet recruiting
A Study to Lower Blood Pressure One Year After Childbirth in Women Who Had Preeclampsia
Adverse Pregnancy Outcomes, Cardiovascular Diseases
Active, not recruitingObservational study
Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients With Homozygous Familial Hypercholesterolemia
Homozygous Familial Hypercholesterolemia (HoFH), Major Adverse Cardiovascular Events (MACE)
RecruitingPhase 2
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
Atherosclerosis, Cardiovascular Disease
Not yet recruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
Obesity, Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Rajesh Vedanthan, MD, MPH principal investigator
NYU Langone Health
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Usual Clinical Care, Group Medical Visits and Microfinance Groups in people with Cardiovascular Disease and Diabetes, run by NYU Langone Health at 1 site in Kenya.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Jun 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Kenya. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Systolic Blood Pressure (time frame: Baseline and 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02501746, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jun 2020; AzTrials last refreshed its copy on 4 Nov 2026.